相关实验视频

Updated: Jun 16, 2025

A Decentralized Ex Vivo Murine Bladder Model with the Detrusor Muscle Removed for Direct Access to the Suburothelium during Bladder Filling

A Decentralized Ex Vivo Murine Bladder Model with the Detrusor Muscle Removed for Direct Access to the Suburothelium during Bladder Filling

Published on: November 28, 2019

在过度活跃的膀中向药物输送的乳酸菌-多多巴胺系统:来自膀细胞球体,老鼠模型和尿道微生物群分析的证据

Xiaolong Wang^1,2, Guanyi Wang², Peibin Cen¹

¹Department of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People's Republic of China.

International journal of nanomedicine

|August 20, 2024

概括

一种新的Lactobacillus-polydopamine纳米粒子系统有效地将药物直接输送到膀壁,改善过度活性膀 (OAB) 治疗. 这种向性细菌疗法为系统性OAB药物提供了一个有希望的替代品.

科学领域:

生物医学工程生物医学工程
纳米技术纳米技术
微生物学微生物学

背景情况:

过度活跃的膀 (OAB) 由于治疗效果有限,副作用有限,患者遵守规则较差,因此存在重大挑战.
需要针对膀壁的新型药物输送系统来改善OAB治疗.

研究的目的:

探索一个聚多巴胺 (PDA) 覆盖的乳酸菌平台作为局部OAB治疗的新型载体.
为了评估这种乳杆菌-PDA系统 (LPS) 在OAB大鼠模型中提供抗糖药索利芬素的疗效.

主要方法:

尿路微生物组分析,以确定健康群体和OAB群体中的乳酸菌患病率.
乳酸菌-PDA纳米颗粒的合成和表征.
使用老鼠膀 perfusion 模型和人类膀光滑肌肉细胞球体的纳米粒子分布和透的评估.
在OAB大鼠模型中评估LPS疗效.

主要成果:

乳酸菌被确定为健康和OAB个体的尿道微生物群中占主导地位的基因.
合成的Lactobacillus-PDA纳米颗粒显示出统一的尺寸和光学特性.
纳米颗粒显示成功分布和透到膀组织,没有观察到毒性.
这种LPS有效地输送了索利费纳,从而改善了OAB大鼠模型中的治疗结果.

结论:

乳杆菌-PDA系统 (LPS) 显示出作为OAB治疗的向药物载体的显著前景.
这种利用益生菌和纳米颗粒的细菌疗法方法可以克服与当前系统性OAB药物相关的局限性.
覆盖PDA的乳酸菌能够透到膀组织的能力支持其在OAB治疗中局部药物输送的潜力.

关键词:

药物输送是药物输送的过程.乳酸菌种 (lactobacillus) 是一种乳酸菌.纳米材料是纳米材料.过度活动的膀聚多巴胺胺是一种多多巴胺胺.

更多相关视频

Evaluation of Biomaterials for Bladder Augmentation using Cystometric Analyses in Various Rodent Models

Evaluation of Biomaterials for Bladder Augmentation using Cystometric Analyses in Various Rodent Models

Published on: August 9, 2012

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

Published on: July 28, 2012

相关概念视频

Drugs for Treatment of Diarrhea-Predominant IBS

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

Drugs for Treatment of Constipation-Predominant IBS

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...